黛力新联合心痛定对Oddi括约肌功能障碍的治疗价值

目的观察黛力新、心痛定及两者联合对Oddi括约肌功能障碍(SOD)的疗效。方法根据患者病史、临床表现、MRCP、ERCP检查及肝功能改变等进行综合诊断,对诊断为SOD的73例患者分为黛力新单药A组22例、心痛定单药B组25例及两者联合C组26例,治疗四周后,对疗效进行分析。结果 A组有效率为22.72%(5/22),B组有效率为52%(13/25),C组为80.77%(21/26),三组间有效率相比其差异具有统计学意义,两者联合治疗C组明显优于黛力新或心痛定的单药应用。结论对SOD患者药物治疗是首选,联合黛力新、心痛定疗效更佳,对药物治疗不佳或失败者,可选择EST手术治疗。

The Therapeutic Value of Deanxit Combined with Nifedipine in Treating Sphincter of Oddi Dysfunction

Objective To observe the efficacy of deanxit combined with nifedipine in treating sphincter of oddi dysfunction (SOD). Methods 73 patients with SOD were randomly divided into three groups. Group A (n = 22) were treated with single deanxit, group B (n = 25) were treated with single nifedipine, group C (n = 26) were treated with deanxit conbined with nifedipine. The curative effects were com- pared 4 weeks after treatment. Results The effective rate of group A, group B and group C were 22.72%, 52.00% and 80.77% respectively. Group A, group B and group C had statistically significant difference in efficiency by each group pairwise comparisons. The effective rate of group C was significantly higher than group A or group B. Conclusions For patients with sphincter of oddi dysfunction, medicine treatment should be the preferred choice. The clinical effect of combination treatment with deanxit and nifedipine is better than the single-agent. But for those who are ineffective to medicine, endoscopic sphincterotomy (EST) may be the better choice for safety and effectiveness.